Health Care [ 2/12 ] | Biotechnology [ 19/74 ]
NASDAQ | Common Stock
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage.
The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024.
Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 5, 26 | 0.27 Increased by +145.45% | 0.32 Decreased by -16.67% |
| Feb 24, 26 | 0.17 Increased by +241.67% | 0.40 Decreased by -57.50% |
| Oct 28, 25 | 0.23 Increased by +227.78% | 0.37 Decreased by -37.84% |
| Jul 29, 25 | 0.23 Increased by +483.33% | 0.26 Decreased by -11.54% |
| Apr 29, 25 | 0.11 Increased by +144.00% | 0.28 Decreased by -60.71% |
| Feb 25, 25 | -0.12 Decreased by -134.29% | 0.02 Decreased by -700.00% |
| Oct 29, 24 | -0.18 Increased by +10.00% | 0.07 Decreased by -357.14% |
| Jul 23, 24 | -0.06 Decreased by -128.57% | 0.01 Decreased by -700.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 214.27 M Increased by +55.51% | 22.59 M Increased by +164.57% | Increased by +10.54% Increased by +70.14% |
| Dec 31, 25 | 202.13 M Increased by +64.95% | 14.20 M Increased by +259.75% | Increased by +7.02% Increased by +196.85% |
| Sep 30, 25 | 180.85 M Increased by +61.17% | 18.43 M Increased by +245.24% | Increased by +10.19% Increased by +190.11% |
| Jun 30, 25 | 156.80 M Increased by +44.34% | 17.83 M Increased by +556.29% | Increased by +11.37% Increased by +416.13% |
| Mar 31, 25 | 137.78 M Increased by +72.54% | 8.54 M Increased by +148.23% | Increased by +6.20% Increased by +127.95% |
| Dec 31, 24 | 122.54 M Increased by +46.93% | -8.89 M Decreased by -135.22% | Decreased by -7.25% Decreased by -123.97% |
| Sep 30, 24 | 112.21 M Increased by +67.37% | -12.69 M Increased by +8.39% | Decreased by -11.31% Increased by +45.26% |
| Jun 30, 24 | 108.63 M Increased by +51.99% | -3.91 M Decreased by -126.10% | Decreased by -3.60% Decreased by -117.17% |